Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Telik has announced notification of FDA orphan drug designation to ezatiostat HCL (Telintra) for the treatment of myelodysplastic syndrome (MDS).
Subscribe to our email newsletter
The novel inhibitor of the enzyme glutathione S-transferase P1 1,Telintra activates Jun kinase, which regulates cellular growth and differentiation of blood precursor cells.
Telintra investigational agent is being developed for the treatment of MDS and idiopathic chronic neutropenia.
According to earlier studies, Telintra demonstrated clinically significant and sustained reduction in red blood cell transfusions, transfusion independence and multilineage responses in MDS patients.